{
  "symbol": "STTK",
  "company_name": "Shattuck Labs Inc",
  "ir_website": "https://ir.shattucklabs.com/investors/default.aspx",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.shattucklabs.com/investors/news-events/press-releases/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Press Releases\n\nSelecting a year value will change the news content\n\nSelect Year:\n\n2024202320222021202020192017\n\nShowing 2024 undefined News\n\nNovember 25, 2024 \n\n[Shattuck Labs Announces Participation in Upcoming December Conferences](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-December-Conferences/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-December-Conferences/default.aspx)\n\nNovember 14, 2024 \n\n[Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\nOctober 1, 2024 \n\n[Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Provides-Company-Update-and-Announces-SL-325-a-First-In-Class-Death-Receptor-3-DR3-Antagonist-Targeting-the-TL1ADR3-Signaling-Pathway/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Provides-Company-Update-and-Announces-SL-325-a-First-In-Class-Death-Receptor-3-DR3-Antagonist-Targeting-the-TL1ADR3-Signaling-Pathway/default.aspx)\n\nAugust 1, 2024 \n\n[Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Second-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Second-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\nJuly 30, 2024 \n\n[Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-BTIG-Virtual-Biotechnology-Conference/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-BTIG-Virtual-Biotechnology-Conference/default.aspx)\n\nJuly 1, 2024 \n\n[Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes/default.aspx)\n\nJune 14, 2024 \n\n[Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Updated-Positive-Interim-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-in-Combination-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS-and-TP53-mutant-TP53m-Acute-Myeloid-Leuke/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Updated-Positive-Interim-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-in-Combination-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS-and-TP53-mutant-TP53m-Acute-Myeloid-Leuke/default.aspx)\n\nJune 10, 2024 \n\n[Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Orphan-Drug-Designation-Granted-by-the-U.S.-Food-and-Drug-Administration-FDA-for-SL-172154-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Orphan-Drug-Designation-Granted-by-the-U.S.-Food-and-Drug-Administration-FDA-for-SL-172154-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML/default.aspx)\n\nJune 6, 2024 \n\n[Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-to-Host-Investor-Call-and-Webcast-on-Additional-Interim-Data-Presented-at-the-European-Hematology-Association-EHA-2024-Congress-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-M/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-to-Host-Investor-Call-and-Webcast-on-Additional-Interim-Data-Presented-at-the-European-Hematology-Association-EHA-2024-Congress-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-M/default.aspx)\n\nMay 14, 2024 \n\n[Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-to-Present-Additional-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS-and-TP53-mutant-TP53m-Acute-Myeloid-Leukemia-AML-Patients-at-the-Euro/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-to-Present-Additional-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS-and-TP53-mutant-TP53m-Acute-Myeloid-Leukemia-AML-Patients-at-the-Euro/default.aspx)\n\nMay 2, 2024 \n\n[Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\nApril 9, 2024 \n\n[Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Oral-Presentation-of-Preclinical-Data-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Oral-Presentation-of-Preclinical-Data-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024/default.aspx)\n\nApril 1, 2024 \n\n[Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-23rd-Annual-Needham-Virtual-Healthcare-Conference/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-23rd-Annual-Needham-Virtual-Healthcare-Conference/default.aspx)\n\nMarch 4, 2024 \n\n[Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Appointment-of-Clay-Siegall-Ph.D.-and-Kate-Sasser-Ph.D.-to-its-Board-of-Directors/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Appointment-of-Clay-Siegall-Ph.D.-and-Kate-Sasser-Ph.D.-to-its-Board-of-Directors/default.aspx)\n\nFebruary 29, 2024 \n\n[Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\nFebruary 26, 2024 \n\n[Shattuck Labs Announces Participation in Upcoming March Conferences](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-March-Conferences/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Participation-in-Upcoming-March-Conferences/default.aspx)\n\nFebruary 13, 2024 \n\n[Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Enters-into-Strategic-Collaboration-and-License-Agreement-with-Ono-Pharmaceutical-to-Generate-Bifunctional-Fusion-Proteins-for-the-Treatment-of-Autoimmune-and-Inflammatory-Diseases/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Enters-into-Strategic-Collaboration-and-License-Agreement-with-Ono-Pharmaceutical-to-Generate-Bifunctional-Fusion-Proteins-for-the-Treatment-of-Autoimmune-and-Inflammatory-Diseases/default.aspx)\n\nJanuary 8, 2024 \n\n[Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Provides-Corporate-Update-and-Highlights-Upcoming-Key-Milestones-in-2024/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Provides-Corporate-Update-and-Highlights-Upcoming-Key-Milestones-in-2024/default.aspx)\n\nJanuary 4, 2024 \n\n[Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Presentation-at-Upcoming-42nd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx)\n\n[Read More](/investors/news-events/press-releases/news-details/2024/Shattuck-Labs-Announces-Presentation-at-Upcoming-42nd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx)\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        },
        {
          "title": "Events & Presentations",
          "url": "https://ir.shattucklabs.com/investors/news-events/events-and-presentations/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Events & Presentations\n\n##  Upcoming Events\n\n##  Featured Presentation\n\nNovember 14, 2024\n\nNovember 14, 2024 Shattuck Labs Corporate Presentation\n\n[ Download (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Nov/14/Shattuck-Labs_Corporate-Presentation_November-14-2024_VF.pdf)\n\n##  Past Events\n\nSelecting a year value will change the event content\n\nSelect year:\n\n20242023202220212020\n\nShowing events from year 2024\n\nOctober 1, 2024 8:00 AM ET\n\n[Company Update and Announcement of SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist](/investors/news-events/events-and-presentations/events/event-details/2024/Shattuck-Labs-Announces-Company-Update-and-Outlines-Strategic-Pipeline-Prioritization/default.aspx)\n\n[ Webcast (opens in new window) ](https://events.q4inc.com/attendee/393802079)\n\nAugust 5, 2024 2:00 PM ET\n\n[BTIG Virtual Biotechnology Conference](/investors/news-events/events-and-presentations/events/event-details/2024/BTIG-Virtual-Biotechnology-Conference-2024-zZFvJbLWVq/default.aspx)\n\nVirtual\n\nJune 14, 2024 7:30 AM ET\n\n[Shattuck Labs EHA 2024 Conference Call](/investors/news-events/events-and-presentations/events/event-details/2024/Shattuck-Labs-EHA-2024-Conference-Call-2024-PdtcXXa683/default.aspx)\n\nVirtual\n\n[ Webcast (opens in new window) ](https://lifescievents.com/event/shattucklabseha2024/)\n\nApril 17, 2024 12:00 PM ET\n\n[Citi's Biotech C-Suite Fireside Chat Series](/investors/news-events/events-and-presentations/events/event-details/2024/Citis-Biotech-C-Suite-Fireside-Chat-Series-2024-S2uECjrbMX/default.aspx)\n\nVirtual\n\n[ Webcast (opens in new window) ](https://shattuck-labs-inc-sttk-apr-24.open-exchange.net/)\n\nApril 8, 2024 1:30 AM ET\n\n[23rd Annual Needham Healthcare Conference](/investors/news-events/events-and-presentations/events/event-details/2024/23rd-Annual-Needham-Healthcare-Conference-2024-6KLZLw_hdw/default.aspx)\n\nVirtual\n\n[ Webcast (opens in new window) ](https://wsw.com/webcast/needham138/sttk/2295956)\n\nMarch 4, 2024 10:30 AM ET\n\n[TD Cowen 44th Annual Health Care Conference](/investors/news-events/events-and-presentations/events/event-details/2024/TD-Cowen-44th-Annual-Health-Care-Conference--2024-z1EYHkrzS3/default.aspx)\n\n[ Webcast (opens in new window) ](https://wsw.com/webcast/cowen154/panel10/2319862)\n\nJanuary 11, 2024 12:00 PM PT\n\n[42nd Annual J.P. Morgan Healthcare Conference](/investors/news-events/events-and-presentations/events/event-details/2024/42nd-Annual-JP-Morgan-Healthcare-Conference--2024-iwpbwGtPL1/default.aspx)\n\nWestin St. Francis, San Francisco, CA\n\n[ Webcast (opens in new window) ](https://jpmorgan.metameetings.net/events/healthcare24/sessions/50086-shattuck-labs/webcast?gpu_only=true&kiosk=true)\n\n##  Past Presentations\n\nSelecting a year value will change the presentation content\n\nSelect year:\n\n202420232022\n\nShowing presentations from year 2024\n\nNovember 14, 2024\n\nNovember 14, 2024 Shattuck Labs Corporate Presentation\n\n[ Download PDF of the presentation, November 14, 2024 Shattuck Labs Corporate Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Nov/14/Shattuck-Labs_Corporate-Presentation_November-14-2024_VF.pdf)\n\nOctober 1, 2024\n\nOctober 1, 2024 Shattuck Labs Corporate Presentation\n\n[ Download PDF of the presentation, October 1, 2024 Shattuck Labs Corporate Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Oct/01/Shattuck-Labs_Corporate-Presentation_October-1-2024_Final.pdf)\n\nAugust 1, 2024\n\nAugust 1, 2024 Shattuck Labs Corporate Presentation\n\n[ Download PDF of the presentation, August 1, 2024 Shattuck Labs Corporate Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Aug/01/shattuck-labs_corporate-presentation_august-01-2024_vf.pdf)\n\nJune 14, 2024\n\nShattuck Labs EHA 2024 Data Presentation\n\n[ Download PDF of the presentation, Shattuck Labs EHA 2024 Data Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Jun/14/Shattuck-Labs-STTK-_EHA-Data-2024_VFINAL.pdf)\n\nMay 2, 2024\n\nMay 02, 2024 Shattuck Labs Corporate Presentation\n\n[ Download PDF of the presentation, May 02, 2024 Shattuck Labs Corporate Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/May/02/shattuck-labs_corporate-presentation_may-2-2024_vf.pdf)\n\nApril 9, 2024\n\nShattuck Labs AACR 2024 TRIM7 Presentation\n\n[ Download PDF of the presentation, Shattuck Labs AACR 2024 TRIM7 Presentation. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Apr/09/shattuck-labs-sttk-_-aacr-2024_trim7_vf.pdf)\n\nFebruary 29, 2024\n\nShattuck Labs Corporate Presentation, February 29, 2024\n\n[ Download PDF of the presentation, Shattuck Labs Corporate Presentation, February 29, 2024. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Feb/29/shattuck-labs_corporate-presentation_feb-29-2024_vf.pdf)\n\nJanuary 8, 2024\n\nShattuck Labs Corporate Presentation, January 8, 2024\n\n[ Download PDF of the presentation, Shattuck Labs Corporate Presentation, January 8, 2024. (opens in new window) ](https://s205.q4cdn.com/862988904/files/doc_presentations/2024/Jan/08/shattuck-labs_corporate-presentation_january-8-2024_vf.pdf)\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        }
      ]
    },
    {
      "section_name": "Stock Info",
      "links": [
        {
          "title": "Stock Quote & Chart",
          "url": "https://ir.shattucklabs.com/investors/stock-info/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Stock Info\n\n## Stock Quote\n\n#### NASDAQ: STTK\n\n  * Price\n\n$1.10\n\n  * Volume\n\n113,256\n\n  * Change\n\n+0.01\n\n  * % Change\n\n+0.92%\n\n  * Today's Open\n\n$1.10\n\n  * Previous Close\n\n$1.09\n\n  * Intraday High\n\n$1.14\n\n  * Intraday Low\n\n$1.10\n\n  * 52 Week High\n\n$11.76\n\n  * 52 Week Low\n\n$0.94\n\n\n\n\nPricing delayed by 20 minutes. Last Updated 11/29/2024 1:00 PM\n\n## Stock Chart\n\n## Historical Stock Quote\n\nLookup Date: 20242023202220212020201920182017201620152014JanFebMarAprMayJunJulAugSepOctNovDec12345678910111213141516171819202122232425262728293031Look Up\n\n#### Stock Quote: NASDAQ: STTK\n\nLoading historical data...\n\n\n\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://ir.shattucklabs.com/investors/stock-info/analyst-coverage/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Analyst Coverage\n\nAnalyst Coverage Table Firm | Analyst  \n---|---  \nCiti | Yigal Nochomovitz, Ph.D.  \nTD Cowen | Marc Frahm, Ph.D.  \nEvercore ISI | Umer Raffat  \nH.C. Wainwright | Joseph Pantginis, Ph.D.  \nNeedham & Company | Gil Blum, Ph.D.  \n  \nShattuck Labs, Inc is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Shattuck Labs, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Shattuck Labs, Inc or its management. Shattuck Labs, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        }
      ]
    },
    {
      "section_name": "Financials",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.shattucklabs.com/investors/financials/sec-filings/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# SEC Filings\n\nSelecting the value will change the page content\n\nSelect Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other\n\nDate Filing Type Filing Description Download / View\n\nLoading ...\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n\n0001680367\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.shattucklabs.com/investors/financials/quarterly-results/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Quarterly Results\n\nLoading slider...\n\n## Financial Summary Table\n\nLoading items...\n\nLoading financial reports...\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        }
      ]
    },
    {
      "section_name": "Governance",
      "links": [
        {
          "title": "Documents & Charters",
          "url": "https://ir.shattucklabs.com/investors/governance/documents-charters/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Documents & Charters\n\n## Documents & Charters\n\nThe Board of Directors of Shattuck Labs, Inc. (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. \n\n## Governance Documents\n\nDownload item year list\n\nDownload Description\n\n[ CODE OF BUSINESS CONDUCT AND ETHICS PDF Format (opens in new window) ](//s205.q4cdn.com/862988904/files/doc_downloads/governance/2024/code-of-conduct-and-business-ethics-6-4-24.pdf)\n\n652 KB\n\n[ Principles Of Corporate Governance PDF Format (opens in new window) ](//s205.q4cdn.com/862988904/files/doc_downloads/governance/sttk-_-corporate-governance-guidelines-10-22-21.pdf)\n\n41 KB\n\n## Committee Charters\n\nDownload item year list\n\nDownload Description\n\n[ Audit Committee PDF Format (opens in new window) ](//s205.q4cdn.com/862988904/files/doc_downloads/charters/Shattuck-Audit-Committee-Charter.pdf)\n\n33 KB\n\n[ Compensation Committee PDF Format (opens in new window) ](//s205.q4cdn.com/862988904/files/doc_downloads/charters/STTK-Compensation-Committee-Charter-FINAL-July-2021.pdf)\n\n19 KB\n\n[ Nominating and Corporate Governance Committee PDF Format (opens in new window) ](//s205.q4cdn.com/862988904/files/doc_downloads/charters/2023/sttk-n-cg-committee-charter-final-august-2022.pdf)\n\n8 KB\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://ir.shattucklabs.com/investors/governance/committee-composition/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Committee Composition\n\nAudit Committee  |  Compensation Committee  |  Nominating and Corporate Governance Committee   \n---|---|---  \nHelen Boudreau  \nTyler Brous  \nCarrie Brownstein  \nNeil Gibson  \nGeorge Golumbeski  \nClay Siegall  \nKate Sasser  \n  \n#### \n\nAudit Committee\n\nHelen Boudreau\n\nTyler Brous\n\nNeil Gibson\n\n#### \n\nCompensation Committee\n\nTyler Brous\n\nGeorge Golumbeski\n\nClay Siegall\n\n#### \n\nNominating and Corporate Governance Committee\n\nCarrie Brownstein\n\nNeil Gibson\n\nKate Sasser\n\n  * Financial Expert\n  * Board Chair\n  * Committee Member\n  * Committee Chair\n\n\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        }
      ]
    },
    {
      "section_name": "Resources",
      "links": [
        {
          "title": "FAQs",
          "url": "https://ir.shattucklabs.com/investors/resources/faqs/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# FAQs\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://ir.shattucklabs.com/investors/resources/email-alerts/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Email Alerts\n\n## Subscribe To Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\nFor further information on how we protect your information, please refer to our [Privacy Policy](https://www.shattucklabs.com/privacy-policy/\n).\n\n## \n\n## Unsubscribe From Investor Email Alerts \n\nTo opt-out of investor email alerts, please enter your email address in the field below and you will be removed from all investor relations email alerts to which you are subscribed. After submitting your email, you will receive a confirmation email to the requested email address. You must click the confirmation link in order to complete your request to unsubscribe. You can elect to receive investor alerts at any time you would like.\n\n* Required\n\nEmail Address *  \n---  \n  \nUnsubscribe\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        },
        {
          "title": "Investor Contact",
          "url": "https://ir.shattucklabs.com/investors/resources/ir-media-contact/default.aspx",
          "content": "[Skip to main content](#maincontent)\n\n[![Shattuck Labs Corpt site](//s205.q4cdn.com/862988904/files/design/logo-white.png)](https://www.shattucklabs.com/)\n\n# Investor Contact\n\n### Investor Relations and Media Contact\n\nConor Richardson, CPA, IRC Senior Director, Finance & Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### INVESTOR CONTACT\n\nConor Richardson, CPA, IRC Vice President of Investor Relations\n\n[512-220-1527](tel:512-220-1527) InvestorRelations@shattucklabs.com\n\n### Quick Links\n\n  * [About](https://www.shattucklabs.com/about/about-overview/)\n  * [Our Science](https://www.shattucklabs.com/our-science/arc-platform/)\n  * [Pipeline](https://www.shattucklabs.com/pipeline/overview/)\n  * [Clinical Trials](https://www.shattucklabs.com/clinical-trials/overview/)\n  * [Investors](https://ir.shattucklabs.com/overview/default.aspx)\n  * [Careers](https://www.shattucklabs.com/careers/intro-to-shattuck/)\n  * [Contact](https://www.shattucklabs.com/locations/locations/)\n\n\n\n### Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt Shattuck Labs, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to Shattuck Labs to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nQuote  \nEvent  \n  \nSubmit Sign Up\n\n[Unsubscribe](/investors/resources/email-alerts/default.aspx#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n[![Shattuck Labs Symbol](//s205.q4cdn.com/862988904/files/design/shattuck-bugLG.png)](https://www.shattucklabs.com/)\n\n© 2024 Shattuck Labs, Inc\n\n[Privacy](https://www.shattucklabs.com/privacy-policy/)[TERMS OF USE](https://www.shattucklabs.com/terms-of-use/) [Follow us on linked in](https://www.linkedin.com/company/shattuck-labs/)\n"
        }
      ]
    }
  ]
}